Behandling af svær astma med biologiske lægemidler hos børn og unge

Katrine Bredsdorff Spangenberg, Uffe Bødtger, Kirsten Skamstrup Hansen, Bo Lund Krogsgaard Chawes

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

Prerequisites for successful treatment of severe asthma in children and adolescents with biological drugs are: 1) systematic assessment, excluding and treating other causes of lack of asthma control, 2) immunological phenotyping of the patient, and 3) choice of biological drug targeting the specific disease mechanism. Anti-immunoglobulin (Ig) E and anti-interleukin (IL)-5 have a clinically relevant effect reducing exacerbation rate, but there is still a need for studies in children and adolescents being treated with anti-IgE and anti-IL-5 as well as newer biological drugs, which affect lung function, asthma control and quality of life.
OriginalsprogDansk
ArtikelnummerV05180364
TidsskriftUgeskrift for Laeger
Vol/bind181
Udgave nummer20
Sider (fra-til)1876-1880
ISSN0041-5782
StatusUdgivet - 14. okt. 2019

Fingeraftryk

Interleukin-5
Pharmaceutical Preparations
Quality of Life
Lung

Citer dette

Spangenberg, K. B., Bødtger, U., Hansen, K. S., & Chawes, B. L. K. (2019). Behandling af svær astma med biologiske lægemidler hos børn og unge. Ugeskrift for Laeger, 181(20), 1876-1880. [V05180364].
Spangenberg, Katrine Bredsdorff ; Bødtger, Uffe ; Hansen, Kirsten Skamstrup ; Chawes, Bo Lund Krogsgaard. / Behandling af svær astma med biologiske lægemidler hos børn og unge. I: Ugeskrift for Laeger. 2019 ; Bind 181, Nr. 20. s. 1876-1880.
@article{6805593387bd44c8ab07eb3b522bc40d,
title = "Behandling af sv{\ae}r astma med biologiske l{\ae}gemidler hos b{\o}rn og unge",
abstract = "Prerequisites for successful treatment of severe asthma in children and adolescents with biological drugs are: 1) systematic assessment, excluding and treating other causes of lack of asthma control, 2) immunological phenotyping of the patient, and 3) choice of biological drug targeting the specific disease mechanism. Anti-immunoglobulin (Ig) E and anti-interleukin (IL)-5 have a clinically relevant effect reducing exacerbation rate, but there is still a need for studies in children and adolescents being treated with anti-IgE and anti-IL-5 as well as newer biological drugs, which affect lung function, asthma control and quality of life.",
keywords = "Severe asthma, Treatment",
author = "Spangenberg, {Katrine Bredsdorff} and Uffe B{\o}dtger and Hansen, {Kirsten Skamstrup} and Chawes, {Bo Lund Krogsgaard}",
year = "2019",
month = "10",
day = "14",
language = "Dansk",
volume = "181",
pages = "1876--1880",
journal = "Ugeskrift for Laeger",
issn = "0041-5782",
publisher = "Almindelige Danske Laegeforening",
number = "20",

}

Spangenberg, KB, Bødtger, U, Hansen, KS & Chawes, BLK 2019, 'Behandling af svær astma med biologiske lægemidler hos børn og unge', Ugeskrift for Laeger, bind 181, nr. 20, V05180364, s. 1876-1880.

Behandling af svær astma med biologiske lægemidler hos børn og unge. / Spangenberg, Katrine Bredsdorff; Bødtger, Uffe; Hansen, Kirsten Skamstrup; Chawes, Bo Lund Krogsgaard.

I: Ugeskrift for Laeger, Bind 181, Nr. 20, V05180364, 14.10.2019, s. 1876-1880.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Behandling af svær astma med biologiske lægemidler hos børn og unge

AU - Spangenberg, Katrine Bredsdorff

AU - Bødtger, Uffe

AU - Hansen, Kirsten Skamstrup

AU - Chawes, Bo Lund Krogsgaard

PY - 2019/10/14

Y1 - 2019/10/14

N2 - Prerequisites for successful treatment of severe asthma in children and adolescents with biological drugs are: 1) systematic assessment, excluding and treating other causes of lack of asthma control, 2) immunological phenotyping of the patient, and 3) choice of biological drug targeting the specific disease mechanism. Anti-immunoglobulin (Ig) E and anti-interleukin (IL)-5 have a clinically relevant effect reducing exacerbation rate, but there is still a need for studies in children and adolescents being treated with anti-IgE and anti-IL-5 as well as newer biological drugs, which affect lung function, asthma control and quality of life.

AB - Prerequisites for successful treatment of severe asthma in children and adolescents with biological drugs are: 1) systematic assessment, excluding and treating other causes of lack of asthma control, 2) immunological phenotyping of the patient, and 3) choice of biological drug targeting the specific disease mechanism. Anti-immunoglobulin (Ig) E and anti-interleukin (IL)-5 have a clinically relevant effect reducing exacerbation rate, but there is still a need for studies in children and adolescents being treated with anti-IgE and anti-IL-5 as well as newer biological drugs, which affect lung function, asthma control and quality of life.

KW - Severe asthma

KW - Treatment

M3 - Tidsskriftartikel

VL - 181

SP - 1876

EP - 1880

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 20

M1 - V05180364

ER -

Spangenberg KB, Bødtger U, Hansen KS, Chawes BLK. Behandling af svær astma med biologiske lægemidler hos børn og unge. Ugeskrift for Laeger. 2019 okt 14;181(20):1876-1880. V05180364.